

Coronavirus, pharmaceutical research and global health

The outbreak of new Coronavirus (2019-nCoV) [was declared public health emergency](#) of international concern (PHEIC) on January 30 by the director general of the World Health Organization (WHO), responding to the rapid spread of this pathology started in China, and which so far has claimed more than 200 lives. This statement shows the dangerous nature of the virus, the need to find effective treatments and strengthen available healthcare systems, even in regions that have not yet been affected, such as Latin America.

In this battle against the unknown, Chinese authorities established quarantines as a preventive measure against the spread of this virus; from FIFARMA, we support the WHO's advice to other countries in order to prevent or reduce the infection of people by secondary transmission, through active surveillance, early detection, isolation, case management. As representatives of the pharmaceutical industry in Latin America, we recognize the importance of promoting international communication and intersectoral collaboration aimed at increasing the knowledge about the virus that drives and advances the corresponding research.

Healthcare systems and organizations, companies, members and allies of the pharmaceutical industry work collectively in the performance of diagnoses, the provision of pharmaceutical products, medicines and protectors that increase the pace of investigations necessary for the development of vaccines and treatments for this type of epidemics and other diseases that threaten global health.

Resources:

[About the coronavirus - WHO](#)
[International Emergency - Public Health](#)
[Virus aspects - BBC](#)
[Infectious outbreak – BBC](#)

